Search

Your search keyword '"Recurrent osteosarcoma"' showing total 41 results

Search Constraints

Start Over You searched for: Descriptor "Recurrent osteosarcoma" Remove constraint Descriptor: "Recurrent osteosarcoma"
41 results on '"Recurrent osteosarcoma"'

Search Results

2. Injectable hydrogels for Fenton-like Mn2+/Fe2+ delivery with enhanced chemodynamic therapy prevent osteosarcoma recurrence and promote wound healing after excision surgery

Catalog

Books, media, physical & digital resources

3. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Childrens Oncology Group.

4. Recurrent Osteosarcoma Presenting as Hepatic Metastasis: A Case Report.

5. Abdominal Wall Reconstruction with a Free Fibula Flap after Internal Extended Hemipelvectomy

7. Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

8. HER2-Targeted Therapy in Osteosarcoma

9. The lncRNAs RP1-261G23.7, RP11-69E11.4 and SATB2-AS1 are a novel clinical signature for predicting recurrent osteosarcoma

10. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.

11. Recurrent Osteosarcoma Presenting as an Isolated Bone Marrow Relapse

12. Updated outcomes for patients with completely resected pulmonary recurrent osteosarcoma: A report from the Children’s Oncology Group

13. Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma

14. Comparison of18F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma

15. Characterizing the landscape of genomic variants in high-risk pediatric osteosarcoma

16. Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children’s Oncology Group

17. Late post-operative recurrent osteosarcoma: Three case reports with a review of the literature

18. Retrospective analysis of prognostic factors for sixty osteosarcoma patients with local recurrence

19. Hyperthermia in the Treatment of Post-Actinic Osteosarcomas: Our Anecdotal Experience

20. Limb Salvage Strategy by Intra-Arterial Chemotherapy for Local Recurrent Osteosarcoma in Extremities

21. Recurrent Bone Tumors

22. A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma

23. Gemcitabine With or Without Docetaxel and Resection for Recurrent Osteosarcoma

25. Recurrent osteosarcoma with calcified liver metastases: Uncommon development of a common disease

26. Oncogenic Osteomalacia as a Harbinger of Recurrent Osteosarcoma

27. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group.

28. (99m)Tc-MDP- and (18F)-FDG-avid florid reactive periostitis ossificans mimicking recurrent osteosarcoma

29. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

30. Recurrent osteosarcoma of maxilla presenting as fungating mass: A case report

31. Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward

32. Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma

33. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy

34. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)

35. Case 16: Successful Delivery After a Hemipelvectomy in a 28-Year-Old Woman with Recurrent Osteosarcoma of the Proximal Femur

36. A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung

37. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma

38. Michael S. Aldrich, MD (1949–2000)

39. Totally implantable venous access system (TIVAS) Complicated by Tracheo-Venous Fistula

40. Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled